- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04818853
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI) (CAPA IFI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Rachel McMullen, BS
- Phone Number: 2059347292
- Email: rlmcmullen@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- The University of Alabama at Birmingham
-
Principal Investigator:
- Peter Pappas, MD
-
Contact:
- Rachel McMullen, BS
- Phone Number: 205-934-7292
- Email: rlmcmullen@uabmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Adult Intensive Care Unit Patients with SARS-CoV2 requiring greater than 72 hours of mechanical ventilation.
Participating sites include: University of Alabama at Birmingham, University of Pittsburgh, Washington University in St. Louis, University of California at Davis, University of Texas at Houston, University of Maryland, and University of Texas Health Sciences Center at San Antonio, Cornell University and Columbia/Presbyterian Medical Center
Description
Inclusion Criteria:
- Adults aged 18 years or older at the time of enrollment
- SARS-COV2 positivity by PCR with respiratory failure requiring mechanical ventilation for at least 72 hours
- Prior therapy with antifungals, including prophylaxis, is NOT an exclusion.
Exclusion Criteria:
- Life expectancy of less than 72 hours as determined by the site investigator.
- Expected to be weaned from mechanical ventilation in next 24 hours
- Care received in any setting other than an intensive care unit (ICU) at the time of enrollment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
COVID Patients with Aspergillosis and Other fungal Infections
All patients have been diagnosed with COVID-19.
The purpose of this study is to look at this group of patients in the potential to develop Aspergillosis and other fungal infections.
|
We will be receiving discarded specimens weekly.
From these we are going to identify these various potential infections.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants requiring mechanical ventilation
Time Frame: 72 hours or greater
|
Number of patients placed on a ventilator
|
72 hours or greater
|
Participants with all cause mortality
Time Frame: In 30 days
|
Participants with all cause mortality in SARS-CoV-2
|
In 30 days
|
Participants with all cause mortality
Time Frame: In 60 days
|
Participants with all cause mortality in SARS-CoV-2
|
In 60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants at risk for developing CAPA or IFIs
Time Frame: 180 days
|
Risk factors associated with patients who are at risk for CAPA or IFIs
|
180 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Peter Pappas, MD, The University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Bacterial Infections and Mycoses
- Lung Diseases, Fungal
- COVID-19
- Infections
- Communicable Diseases
- Mycoses
- Invasive Fungal Infections
- Aspergillosis
- Pulmonary Aspergillosis
Other Study ID Numbers
- IRB-300006311
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Observation to monitor patients for these infections
-
Centre Hospitalier René DubosCompletedBacillus Cereus Infection
-
Assistance Publique - Hôpitaux de ParisRecruitingKeratitis | EndophthalmitisFrance
-
Williams LifeSkillsDuke UniversityCompletedFocus Whether After Implant Pre-AICD Video Was HelpfulUnited States
-
Hasselt UniversityCompleted
-
xCuresCancer Commons; Genetic Alliance; LunaDNA; REDCap CloudCompleted
-
Ankara UniversityCompleted
-
Federal University of BahiaConselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de...CompletedInappropriate Prescribing
-
Imperial College LondonBiomedical Research and Training InstituteCompleted
-
Turku University HospitalTurku AMK Master SchoolCompleted
-
Tahel Ilan BerUnknownInflammatory Bowel Diseases